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Bovine placental lactogen (bPL) is a hormone produced by the fetal portion of the
placenta during gestation. Although there is little known about the structure and function
of the protein, it is thought to play a role in the growth of the fetus and in mammary
growth and differentiation. Attempts have been made to heighten the understanding of
bPL through the use of recombinant DNA technology. Thus far, researchers have been
able to produce the recombinant molecule in bacteria cells. Bacteria, however, are
incapable of carrying out some of the post-translational modifications characteristic of
mammalian proteins. For example, unlike native bPL, recombinant bPL is nonglycosylated. Other examples of post-translational modifications include disulfide bond
formation and correct folding of the protein. The aim of this study, therefore, was to
clone the bPL cDNA into a mammalian expression vector, amplify the recombinant
molecule in E. coli cells, and transfect the rbPL into mouse fibroblast cells. The idea

behind this research was that the mouse cells would be able to produce the bPL complete
with the post-tanslational modifications seen in the native protein.
The bPL cDNA was successfully cloned into the pcDNA3.1(+) vector and the
recombinant molecule was transformed into E. coli cells. The bPL sequence isolated in
this study was similar to that isolated by Schuler et al. (1988), who were able to divide
the gene into five exons. The bPL gene in this study was missing the third exon, which
contains a cysteine residue that is likely involved in the proper folding of the mature
protein.
Attempts were made to transfect the pcDNA3.1-bPL into mouse L929 cells. Media
was collected post-transfection and assayed (Wallace, 1993) for the presence of bPL. An
average concentration of 1 ng/mL bPL was measured. It was also noted that the
transfected cells, as compared to control non-transfected cells, grew at a slower rate.
Initially, it was suspected that the L929 cells were infected with mycoplasma.
Transfection of a new batch of mouse cells showed improved growth rate, but did not
produce a higher transfection efficiency. Studies with ovine placental lactogen have
shown that the 5' flanking sequence of the PL gene is important in the production of the
protein. In this study, the 5' flanking region of the bPL gene was removed during the
making of the recombinant bPL molecule. It is therefore hypothesized that the 5'
flanking sequence of the bPL gene is important to the production of the protein due to the
low transfection efficiency observed.
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Chapter 1
LITERATURE REVIEW
Introduction
During pregnancy, a modification in the dam's endocrine production is responsible for
keeping her offspring alive. Hormones secreted in this crucial period work to maintain
the fetus and assist the dam in preparing for lactation (Senger, 1999). In 1905, Halban
was the first to suggest that the hormonal changes noted during gestation could be
attributed to the newly formed placenta instead of to some preexisting organ. Since then,
a hormone referred to as placental lactogen (PL) has been identified in primates (Kaplan
and Grumbach, 1964; Vinik et al, 1973; Blank et al, 1977), rodents (Blank et al, 1977),
and ruminants (Martal and Djiane, 1975; Chan et al, 1976; Hurley et al, 1977; Becka el
al, 1977; Currie ef al, 1990).
The focus of this study is on bovine placental lactogen (bPL). bPL has proven to be
quite difficult to study since such low levels are found in the circulation of the cow
during pregnancy (Byatt et al, 1992b). The hormone has been purified from both
placental homogenates (Murthy et al, 1982) and secretory vesicles (Byatt et al, 1986), a
grueling process that produces relatively low yields. The aim of this research, therefore,
is to produce bovine placental lactogen in the laboratory by means of genetic cloning
techniques, so that we may gain a better understanding of the structure and function of
the hormone.
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Biosynthesis of bPL
The placenta is a temporary endocrine organ whose purpose is to mediate metabolic
exchange between the mother and fetus during pregnancy (Anthony et al, 1995).
Surrounding the placenta is a layer of cells known as trophoblast cells, approximately
twenty percent of which are binucleated (Schlafer et al, 2000). These binucleated cells
appear between days eighteen and twenty in the cow and are formed continuously
throughout gestation (Senger, 1999). Biosynthesis of placental lactogen, along with other
pregnancy maintenance hormones and growth factors, takes place within these cells.
After production, the hormone is stored in the cells' membrane-bound secretory granules
(Verstegen et al, 1985; Duello et al, 1986; Rice and Thorburn, 1986). It is not until day
thirty-six that placental lactogen is detectable in the trophoblastic tissue (Buttle and
Forsyth, 1976), and synthesis of the hormone continues throughout the duration of
pregnancy.
Binucleate trophoblast cells are characterized by their ability to migrate into the
maternal epithelium (Wooding and Wathes, 1980). It was hypothesized that they do so in
order to transfer a large, non-diffusible molecule across the fetal-maternal microvillar
junction to the maternal circulation. The possible stages involved in binucleate cell
migration are diagrammed in Figure 1.1. The fetal binucleate cells are formed in the
chorion, where they synthesize the granules needed for storing the placental lactogen.
The cells move toward and make contact with the basement membrane of the uterine
epithelium, crossing the microvillar junction en route. The granules remain in the fetal
portion of the cell until the majority of the cell has made its way into the uterine
epithelium (Wooding and Wathes, 1980). A hybrid cell is formed from the fusion of the
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Maternal capillary

Fetal capillary

Figure 1.1. Possible stages involved in binucleate cell migration. (1) A fetal binucleate
cell is formed in the chorionic epithelium and synthesizes the granules needed for storage
of the placental lactogen. (2) The cell makes contact with the microvillar junction. (3) It
crosses the microvillar junction and approaches the basement membrane of the uterine
epithelium. The granules remain in the fetal portion of the binucleate cell. (4) The
uterine epithelium contains the majority of the cell. The granules are now scattered
throughout the entire cell or are localized in the maternal end of the cell. (5) The
granules have been released into the maternal circulation. The binucleate cell appears to
have reduced cytoplasm and shrunken, dense nuclei. (6) The binucleate cell is eventually
taken up by a chorion epithelial cell vacuole. Diagram adapted from Wooding and
Wathes(1980).
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binucleate trophoblast cell with the maternal cell. This hybrid cell is referred to as a
trinucleate "giant" cell (Wooding and Beckers, 1987). Once the two cells fuse, the
granules containing the placental lactogen are released, thus allowing the entrance of the
placental lactogen into the maternal circulation. Wooding found no evidence of
degranulation before migration (Wooding, 1987; Wooding and Beckers, 1987). After
the granules are released, the binucleate cells appear to have reduced cytoplasm and
shrunken, dense nuclei. These cells are eventually taken up by the chorion epithelial cell
vacuoles (Wooding and Wathes, 1980).

Structure of bPL
Ruminant placental lactogens are members of the growth hormone(GH)/prolactin
(PRL) gene family. Despite their many similarities, there is a 10,000 molecular weight
difference between bPL and the placental lactogens found within sheep and goats, oPL
and cPL respectively. Ovine and caprine placental lactogens are single-chain
polypeptides with molecular weights of 21,000 to 23,000 and intramolecular disulfide
bonds (Chatterjee and Munro, 1977). In contrast, bPL exhibits a complex glycosylation
pattern (Shimomura and Bremel, 1988; Byatt et al, 1990), a factor that increases its
molecular weight to 31,000 to 33,000 (Beckers et al, 1980; Murthy et al, 1982; Arima
and Bremel, 1983). The amino acid composition of the placental lactogens as a whole
resembles that of GH and pituitary PRL (Chatterjee and Munro, 1977; Hurley et al,
1977, Vinik et al, 1973). More specifically, the gene for bPL has been determined to
translate into a 200 amino acid protein that is 50 and 22% similar to bPRL and bovine
somatotropin (bST), respectively (Schuler et al, 1988).
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bPL Levels Across Gestation
Placental lactogen is found in both the fetal and maternal circulations during
pregnancy. Among the ruminants, cows display the lowest levels of PL. In fact, the
maternal concentration of PL is 100 to 1000 times greater in sheep and goats than in cows
(Byatt et al., 1992b). In the cow, fetal serum concentrations of bPL decline throughout
gestation (Holland et al, 1997), while maternal concentrations peak at day 215 and
remain high until just prior to birth. The highest reported concentration detected in the
maternal serum of the cow was 2.93ng/mL (Wallace, 1993).

Receptor Binding and Biological Activity
In keeping the structural similarity of bPL to bST and bPRL in mind, it seems to
follow suit that bPL would bind with high affinity to both bST and bPRL receptors. This
has, in fact, proven to be the case (Staten et al, 1993; Scott et al, 1992; Gertler et al,
1996). Growth hormone and PRL receptors belong to the cytokine receptor superfamily.
A characteristic of this family of receptors is the need for receptor subunit
homodimerization to initiate signal transduction and ensuing biological activity (Ihle et
al, 1994). bPL, however, does not appear to have the ability to dimerize these receptors
(Staten et al, 1993). This seems to suggest that homodimerization is not essential for
some biological responses signaled through these receptors, since bPL displays both
somatogenic and lactogenic activity. In fact, recombinant bPL (rbPL) has been shown to
stimulate weight gain in mature female rats (Byatt et al, 1991) and mammary
differentiation in steroid-primed dairy heifers (Byatt et al, 1994).
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In 1995, Anthony et al. suggested several possibilities about the identity of the
ruminant placental lactogen receptor using the growth hormone receptor as a model
(Figure 1.2). Ruminant PLs may act by binding to one monomer of the growth hormone
receptor (GHR), to one monomer of the GHR and an undefined monomer, to two
monomers of a variant form of the GHR, or to a receptor that is specific for PL. There
have also been specific binding sites for bPL identified in the bovine endometrium
(Galosy et al, 1991) and corpus luteum (Lucy et al, 1994), suggesting that bPL plays a
role in the maintenance of pregnancy.

Figure 1.2. Possible identity of the ruminant placental lactogen receptor. Ruminant PLs
may bind to: (a) one monomer of the growth hormone receptor (GHR), (b) one monomer
of the GHR and an undefined monomer, (c) two monomers of a variant form of the GHR,
or (d) a receptor that is specific for PL. Diagram adapted from Anthony et al. {1995).
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Recombinant bPL
Recombinant analogues of bPL (rbPL), along with GH, PRL, and a few soluble
extracellular domains of their receptors, have enabled researchers to study the structures
of the hormones and their interactions with their receptors (Gertler, 1997). To date, rbPL
has been produced in bacteria cells. Unlike the native protein, rbPL has not been
glycosylated because bacteria cells are unable to carry out many of the post-translational
modifications that are common in mammalian proteins. Other examples of posttranslational modifications include the formation of disulfide bonds, proper folding of the
protein, and addition of carbohydrate chains.
Disulfide bonds occur between the sulfhydryl groups (-SH) in two cysteine residues of
a protein (Figure 1.3).
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Figure 1.3. Disulfide bond formation. Disulfide bonds are formed between the
sulfhydryl groups (-SH) of two cysteine residues.
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The formation of disulfide bonds is important to the three-dimensional folding of a
protein (http://www.biotech.vt.edu/classes/bion_4784/4GeneExpression/Expression.htmL). Schuler et al. (1988) reported six cysteine residues
in their bPL sequence assumed to form three disulfide bonds similar to those found in
bovine PRL. The intracellular reducing environment of E. coli is not conducive to the
formation of disulfide bonds. In order for disulfide bonds to be formed, it is necessary
for the protein to be transported to the periplasm of the bacteria. This move needs to be
directed by the protein itself, by means of a specific signal sequence in the primary amino
acid sequence (http://www.biotech.vt.edu/classes/bion_4784/4GeneExpression/Expression.htmL).
The proper folding of a protein is accomplished with the help of special proteins
called chaperones. The correct chaperones needed for the folding of mammalian proteins
may not be present within the bacteria cells. The incorrect folding results in the
formation of insoluble aggregates called inclusion bodies
(http://www.biotech.vt.edu/classes/bion_4784/4-GeneExpression/Expression.htmL).
Helman et al. (1998) found that after transformation of their recombinant bPL molecule
into E. coli cells, over 95% of the protein was found in inclusion bodies. A process has
been established to make the protein in inclusion bodies soluble and to refold it, but this
is a process that often fails (http://www.biotech.vt.edu/classes/bion_4784/4GeneExpression/Expression.htmL).
A characteristic of bPL is that it is glycosylated, meaning that it has carbohydrate
groups attached at specific amino acid sequences (Shimomura and Bremel, 1988; Byatt et
al., 1990). Bacteria are not able to add these carbohydrate groups. Studies have shown
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that enzymatic removal of the N-linked oligosaccharides of bPL causes increased binding
to growth hormone receptors (Byatt et at, 1990). rbPL is therefore active, despite the
fact that it is not glycosylated, but it does not resemble the native protein as closely as it
could.
The key to producing bPL that is as close to the native protein as possible is to
produce it in mammalian cells. The mammalian endoplasmic reticulum is a more
suitable environment for disulfide bond formation. In addition, mammalian cells possess
the appropriate chaperones needed for the proper folding of a mammalian protein, and
they are able to add carbohydrates in the correct locations
(http://www.biotech.vt.edu/classes/bion_4784/4-GeneExpression/Expression.htmL). The
aim of this study, therefore, is to clone the bPL cDNA into a mammalian expression
vector and amplify the recombinant molecule in E. coli cells. The final step will be to
transfect the rbPL into mouse cells with the hopes that the mouse cells will be able to
express the hormone complete with the post-translational modifications that are
characteristic of native bPL. The following sections introduce the gene cloning
techniques that will be used to accomplish such a feat.

Gene Cloning
The birth of genetics dates back over a century ago beginning with Gregor Mendel,
who devised a set of rules explaining that inherited traits were controlled by factors called
genes. Next came the discovery of chromosomes by Sutton in 1903 and the development
of techniques for gene mapping by Morgan and his associates in the early 1920s. It was
not, however, until the work of Avery, MacLeod and McCarty in 1944, and of Hershey
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and Chase in 1952, that DNA was identified as the genetic material. Between the years
1952 and 1966 scientists began to understand the structure of DNA, the genetic code, and
the processes of transcription and translation. Finally, in the years 1971-1973 came the
advent of recombinant DNA technology, otherwise known as genetic engineering, the
basis of gene cloning. Gene cloning involves the insertion of a fragment of DNA
carrying a gene into a cloning vector. The cloning vector will then facilitate the entry of
the recombinant molecule into a host organism, where the gene can be amplified. The
next sections will explain the methods involved in the amplification of a gene and the
subsequent in vitro production of the protein that it codes for (Brown, 1995).

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Often times, RNA is isolated from a tissue and used as the starting material for genetic
engineering studies. The cells of that tissue contain the DNA sequence needed to make
up the whole organism, but actually express relatively few of the genes. Only those
genes that are being expressed are transcribed into messenger RNA (mRNA). Extracting
the RNA therefore ensures that the researcher is working with only those genes that are
expressed in the tissue of interest (Brown, 1995).
mRNA cannot be ligated into a cloning vector, so it is necessary to convert it into
DNA by complementary DNA (cDNA) synthesis. This is achieved through the process
known as reverse transcription (RT) in which the enzyme reverse transcriptase is used to
synthesize a DNA strand complementary to an existing RNA strand. The RNA strand is
then degraded, leaving a single-stranded cDNA. It is then possible to proceed with the
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ploymerase chain reaction (PCR), thus amplifying the actual gene of interest (Brown,
1995).
The first step of the PCR is primer design. Primers are generally 17 to 30 base pair
oligonucleotides that correspond to the regions flanking the gene of interest. A primer
that is too short may be able to anneal to a site other than the site directly before the gene,
while a primer that is too long will hybridize at a slower rate, reducing the efficiency of
the PCR. One PCR cycle is composed of three steps: (1) denaturation of the doublestranded DNA, (2) hybridization of the primers to the templates, and (3) DNA synthesis.
The cycle is usually repeated 25-30 times, resulting in the production of several hundred
million copies of the gene (Brown, 1995).
Each step of the PCR is carried out at a particular temperature. Denaturation of the
double-stranded DNA usually takes place at 94°C. At this temperature, the base pairs are
broken releasing single-stranded DNA that can act as templates. The temperature at
which the primers hybridize or anneal to the templates is dependent upon the length and
sequence of the primers themselves. By determining the melting temperature (Tm) of the
primer template hybrid, it is possible to estimate the temperature at which a hybrid would
form. For a primer of 21 base pairs or less the Tm would be calculated as follows:
Tm = (4 x [G + C]) + (2 x [A + T]) °C
in which [G + C] is the number of guanine (G) and cytosine (C) nucleotides in the primer
sequence and [A + T] is the number of adenine (A) and tyrosine (T) nucleotides in the
primer sequence. For a primer that is more than 21 nucleotides in length, the Tm is
calculated as follows:
Tm = 69.3 + (0.41 x [G + C]%) - (650/primer length)
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Where [G + C]% is the percentage of the primer that is made up of either G or C
nucleotides and the primer length is the total number of nucleotides comprising the
primer. The hybridization temperature is usually 1-2°C lower that the calculated Tm.
DNA synthesis usually occurs at 74°C, which is just below the optimum temperature for
Taq polymerase, the enxyme used to facilitate the production of the complementary
strands. Taq polymerase is an ideal enzyme to use because, unlike most DNA
polymerases, it can withstand the high temperatures used during the PCR. Figure 1.2 is a
diagrammatic representation of a RT-PCR (Brown, 1995).

Ligation and Transformation
The DNA fragments resulting from the RT-PCR can now be ligated into a vector to
produce a recombinant DNA molecule. The vector acts as a vehicle to transport the DNA
fragment into a host bacterium. The introduction of the DNA into the living cell is
referred to as transformation. Once inside the host cell, the vector multiplies,
manufacturing numerous copies both of itself and of the DNA fragment that it carries.
Copies of the recombinant molecule are passed on to the progeny of the host cell, where
the vector and the DNA fragment can be replicated further. Eventually, a colony of host
cells is produced, with each cell containing at least one copy of the recombinant
molecule. It is then that the DNA fragment carried by the vector is said to be cloned
(Brown, 1995).
There are two kinds of vectors that are used in gene cloning: plasmids and
bacteriophages. This study will concentrate on plasmids, circular molecules of DNA that
act independently within the bacterial cell. Plasmids often times carry special genes, for
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example, genes that confer antibiotic resistance. Bacteria itself cannot grow in the
presence of antibiotics. However, if the plasmid that it carries has an ampicillin
resistance gene, the bacteria will be able to display resistance to that particular antibiotic.
Therefore, culturing in growth media containing ampicillin would ensure that the
colonies that grow contain the plasmid. Another characteristic of plasmids is that they
have at least one DNA sequence that can act as an origin of replication. This allows the
plasmid to multiply within the host independently of the host's chromosome (Brown,
1995).

Transfection
One problem with using bacteria as hosts for recombinant protein synthesis is that the
bacteria may not process the recombinant protein correctly. Mammalian proteins are
processed after translation by means of chemical modification of the amino acids. The
post-translational modifications, glycosylation for example, which take place are often
essential for the correct biological activity of the protein. Certain post-translational
modifications such as glycosylation are extremely uncommon in bacteria, therefore the
bacterial cells are unable to glycosylate the recombinant protein correclty. Transfecting
the recombinant DNA molecule into mammalian host cells is a way to circumvent this
problem.
Transfection is defined as the process of introducing nucleic acids into cells by nonviral methods. This can be achieved through both chemical and physical means. DEAEdextran, calcium phosphate, and artificial liposomes are examples of chemical reagents
often used to facilitate the transfer of nucleic acids into cultured mammalian cells.
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Physical methods include direct microinjection (Cappechi, 1980), electroporation (Wong
and Neumann, 1982), and biolostic particle delivery (Ye et al, 1990). This study will
focus on the use of artificial liposomes.
Tfx Reagents (Promega), the transfection reagents used in this study, employ cationic
lipids in the delivery of nucleic acids to eukaryotic cells. They are a mixture of the
synthetic cationic lipid molecule N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3di(oleoloxy)-l,4-butanediammonium iodide and the neutral lipid L-dioleoyl
phosphatidylethanolamine (DOPE). The structures of these compounds are shown in
Figure 1.4. Presumably, the cationic portion of the lipid molecule associates with the
negatively charged nucleic acid that is to be transferred into the mammalian cell (Figure
1.5). This creates a lipid/nucleic acid complex with an overall net positive charge. The
complex is then able to closely associate with the negatively charged cell membrane and
is endocytosed by the cell. It has been suggested that DOPE works to release the
complexes from the endosomes so that they may make their way into the nucleus
(Farhood et al, 1995).
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(a)

Figure 1.4. Components of the Tfx transfection reagents. The Tfx reagents (Promega) are
a mixture of (a) the synthetic cationic lipid molecule N,N,N',N'-tetramethyl-N,N,-bis(2hydroxyethyl)-2,3-di(oleoloxy)-l,4-butanediammonium iodide and (b) the neutral lipid
L-dioleoyl phosphatidylethanolamine (DOPE).
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Figure 1.5. Schematic representation of a lipid/nucleic acid complex. The cationic
portion of the lipid molecule associates with the negatively charged nucleic acid. This
creates a lipid/nucleic acid complex with an overall net positive charge. The complex is
then able to closely associate with the negatively charged cell membrane and is
endocytosed by the cell.
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Chapter 2
MATERIALS AND METHODS

RNA Extraction and Reverse Transcription-Polymerase Chain Reaction
Placental tissue was obtained from a Holstein dairy cow that was at day 90 of
gestation at the time of slaughter. The tissue was divided into two 1.5mL eppendorf
tubes, one containing a mass of 140mg and the other 150mg. The two samples were
maintained at -70°C until the time of their use. The initial steps of the bPL cloning
process, the RNA extraction and the reverse transcription-polymerase chain reaction (RTPCR), were performed by Michael Jordan, an undergraduate working on his senior
project under the supervision of Dr. Eric Anderson, PhD.
The RNA was extracted from the samples of placental tissue using the Trizol LS
Reagent protocol from GibcoBRL. The Trizol LS Reagent isolates total RNA from
liquid samples taken from humans, animals, plants, yeast, bacteria, and viruses. As the
samples were being homogenized, the Trizol LS Reagent disrupted the cellular
components, while at the same time keeping the RNA intact. The solution was next
separated into an aqueous phase (containing the RNA) and an organic phase by the
addition of chloroform followed by centrifugation. Once the aqueous phase was
collected, isopropyl alcohol was added to it to precipitate the RNA. The resulting pellet
was washed with 75% ethanol, allowed to dry, and dissolved in 20mL RNase-free H 2 0.
The tubes containing the RNA were stored at -20°C.
Oligonucleotide primers were designed using a known bPL sequence obtained from
GenBank, accession number M33268. This sequence, reported by Yamakawa el al.
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(1990) is detailed in Figure 2.1. Also included in Figure 2.1 are the positions of the
primer sequences, labeled bPL-F (forward) and bPL-R (reverse). The bPL-F primer (5'
CCT CCA TTC AGT CCC TGT TGG 3') was a 21-mer with a melting temperature (Tm)
of 66°C, while the bPL-R primer (5' GAG ACC CAT TAC ACC CAA AC A TG 3') was
a 23-mer with a Tm of 60.6°C. Both primers were obtained from Sigma.
Reverse transcription (RT) was performed on both of the sample tubes containing the
extracted RNA. The reactions were set up as shown in Table 2.1.

Table 2.1. Reverse transcription reactions
Tube
RNA template
bPL-R
1
2ul from 140mg sample
lul
2
2JJ.1 from 150mg sample
lul

_3

°_

RNAse out
lul
lul

H2Q
6ul
6ul

Total volume
lOul
lOul

IH]

M

lOul

It!

The reverse transcription reactions were produced by mixing the RNA template, the bPLR (reverse) primer (Sigma), RNAse out, which destroys RNAses (Sigma), and distilled
water.
Each reaction was incubated at 72°C for two minutes, allowing the primer to anneal to
the template. The RT reaction cocktail (Table 2.2) was then prepared. Reverse
transcription reaction cocktail (Table 2.2) was added to each of the three reaction tubes at
a volume of 5.8ul per tube. The tubes were then incubated at room temperature for 10
minutes, followed by an incubation of 1 hour at 42°C. The resulting products served as
the templates for the polymerase chain reactions (PCR).
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bPL-F
5| g c a c t t c c c c a c c a c a g a t t t c c t c c a t t c a g t c c c t g t t g g g c c a t c t c c c c a t c c a g c
3' c g t g a a g g g g t g g t g t c t a a a g g a g g t a a g t c a g g g a c a a c c c g g t a g a g g g g t a g g t c g

60

a g c a g t c c c t g c a t c c t g g g a t t t c t c t c c a a t cct c|a"Tg|gc t c c a g c a t c t a g c c a t eg 120
tcgtcagggacgtaggaccctaaagagaggt taggagTiccgaggtegtagateggtage
tgggcaccagtggatttgtgaccttgttcgagggtcctgcctgctcctgctgctggtggt
acccgtggtcacctaaacactggaacaagctcccaggacggacgaggacgacgaccacca

180

gtcaaatctactcttgtgccagggtgtggaggattatgcaccatactgtaaaaaccaacc
cagtttagatgagaacacggtcccacacctcctaatacgtggtatgacatttttggttgg

240

tggcaactgccggattccccttcaaagcctgtttgagagagcaacattggtggctagcaa
accgttgacggcctaaggggaagtttcggacaaactctctcgttgtaaccaccgatcgtt

300

caactataggctcgccagggaaatgttcaatgaatttaataaacagtttggcgagggcaa
gttgatatccgagcggtccc
ttacaagttacttaaattatttgtcaaaccgctcccgtt

360

a a a c t tcact t c c a a g g t c a t c a a c a g c t g c c a c a c c g a a t t c a t g a c t a c c c c t a a t a a 420
t t t g a a g t g a a g g t t c c a g t a g t t g t c g a c g g t g t g g c t t a a g t a c t g a t g g g g a t tat t
c a a a g a a g c a g c t g c a a a t a c a g a g g a c g a a g c c c t g t tgaggt tggt t a t c a g t t tget 480
gt t tct t eg t eg a eg tt t a t g t c t c c t g c t t c g g g a c a a c t c c a a c c a a t a g t c a a a c g a
c c a c t c g t g g g a t g a a c c t c t g c a t c a g g c a g t c a c a g a g t tgt t g c a c a g g a a t g g a g c
ggtgagcaccctact tggagacgtagtccgtcagtgtctcaacaacgtgtcct tacctcg

540

ctcacctgatatcttggcaagggctaaagagattgaggacaagaccaaagtacttctaga
600
g a g t g g a c t a t a g a a c c g t t c c c g a t t t c t c t a a c t c c t g t tctggt t t c a t g a a g a t c t
aggtgtggaaatgatacaaaaaagggttcatcctggagagaagaagaacgagccctatcc
tccacacctttactatgttttttcccaagtaggacctctcttcttcttgctcgggatagg

660

agtgtggtcagaaaagtcctccctgacagcagacgatgaggatgtgcgccaaactgcctt
tcacaccagtcttttcaggagggactgtcgtctgctactcctacacgcggtttgacggaa

720

t t a t a g a a t g t t c c a c t g c c t a c a c a g g g a t t c g a g t a a a a t t a g c a c c t a c a t c a a t 11 780
aatatcttacaaggtgacggatgtgtccctaagctcattttaatcgtggatgtagttaaa
get t a a g t g c c g a t t c a c c c c a tgcjt aajgcccacaa t t a a c c c a a c c a g t cct g a g a tgg
cgaattcacggctaagtggggtacgattcgggtgttaattgggttggtcaggactctacc

840

ttacgtgatgatccatcccgtcaaaagcttctttgagttttatagctctttaatgcatgt
aatgcactactaggtagggcagttttcgaagaaactcaaaatatcgagaaat tacgtaca

900

t tgggtgtaatgggtctcatctgaaacaaaataaacacagat tctgtagagatgtcaaaa
aacccacattacccagagtagactttgttttatttgtgtctaagacatctctacagtttt
bPL-R

960

a t c t _ 3'
t a g a a 5'

965

Figure 2.1. bPL sequence obtained from GenBank, accession number M33268.
This sequence originally appeared in a paper written by Yamakawa et al. (1990). The
initiation codon (ATG) and stop codon (TAA) are identified with boxes around them.
The primer sequences (bPL-F and bPL-R) are underlined.
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Table 2.2. Preparation of the reverse transcription reaction cocktail.
Component
Volume per reaction tube
5x RT buffer
3uJ
0.1MDTT
lul
lOmMdNTP
lul
Superscript
Q,8ul
Total volume
5.8ul

Three clean microfuge tubes were obtained and 47.5 ul of the PCR cocktail (Table
2.3) was added to each. Next, 2ul of each template was added to its respective tube. The
control tube (tube 3) received 2ul RNase-free H2O. Taq polymerase was added at a
volume of 0.5ul per reaction tube. The polymerase chain reactions were performed in the
PTC-100 Programmable Thermal Controller (M.J. Research).

Table 2.3. Preparation of the polymerase chain reaction cocktail.
Component
Volume per reaction tube
H20
27.5ul
MgCl2
5ul
1 Ox buffer
5ul
2mM dNTP
5ul
bPL-F
2.5ul
bPL-R
2.5ul
Total volume
47.5ul

Gel Extraction of the PCR Product
A sample of each PCR product (from tubes 1 and 2) was run on agarose (1%) gel
electrophoresis and the bPL DNA fragments were excised using a scalpel. The QIAquick
Gel Extraction Kit (QIAGEN) was used to extract and purify the DNA from each gel
slice. The volumes of buffer QG and isopropanol used during the purification process
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were based on the masses of the excised gel slices. The gel slices were weighed and 3
volumes of buffer QG were added per one volume of gel. Likewise, one gel volume of
isopropanol was added at the appropriate time. The volumes used are outlined in Table
2.4. The optional step 9 was followed and the DNA was eluted with water.

Table 2.4. Reagent volumes used in the gel extraction of bPL.
Mass of placental tissue
Mass of gel slice
Buffer QG
Isopropanol
140mg
HOmg
330ul
~~ HOul
150mg
120mg
360ul
120u1
The mass of each gel slice was used to determine the volumes of buffer QG and
isopropanol used in the gel extraction process.

The purified bPL insert originating from the HOmg sample of placental tissue was used
in the following ligation step.

Ligation of bPL with the pTarget Mammalian Expression Vector
The purified bPL insert was next ligated into the pTarget Mammalian Expression
Vector (Figure 2.2) from Promega. In order to accomplish this, three ligation reactions
were set up (Table 2.5). Each reaction was brought to a total volume of lOul with the
addition of sterile dL^O. The reactions were then kept at 4°C overnight (18 hours),
resulting in the production of recombinant pTarget-bPL molecules.

21

Table 2.5. Reactions set up for the ligation of the bPL insert into the pTarget vector.
Components
Ligation 1
Ligation 2
Ligation 3
Vector
luj
1^x1
lul
bPL insert
2.5ul
5ul
7ul
lOx ligation buffer
1 jn.1
lul
1 jul
Sterile dH 2 0
4.5^1
2^1
0
T4 DNA Ligase
ljjj
ljol
1^1
The components of the three ligation reactions are listed above. The lOx ligation buffer
and T4 DNA ligase were provided along with the pTarget vector (Promega).
Transformation of Recombinant pTarget-bPL into E. coli Cells
One tenth dilutions of each ligation product were made by adding lul recombinant
DNA to 9ul sterile dH20. Three eppendorf tubes were placed on ice. A volume of 50ul
competent JM109 E. coli cells was added to each tube, along with 1 ul of the
corresponding DNA dilution. The tubes were kept on ice for 30 minutes, placed at 42°C
for 45 seconds, and then returned to the ice for 2 minutes. At the end of that time, 500uJ
SOC broth (sterile solution that supplies amino acids and other nutrients) was added to
each tube. The tubes were then placed in the 37°C shaker (set at 220rpm) for 1 hour.
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Bgl II 5665
SgfI 664

Intron

pTarget Vector
(5670 bp)

Synthetic poly(A)

Cytomegalovirus immediate early
enhancer/promoter: bases 1 -750

•

SV40 late polyadenylation signal:
bases 1535-1755

SV40 enhancer/early promoter:
bases 2260-2630

Neomycin selectable marker:
bases 2675-3469

Phage fl region: bases 1798-2252

I"""! Ampicillin resistance gene:
L J bases 3978-4838

Figure 2.2. Map of the pTarget mammalian expression vector. This map is based on the
map provided by Promega.
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Plating the Transfbrmants
The transformants were plated on LB/Amp/IPTG/X-gal plates (lOOug/mL ampicillin,
0.5mM IPTG, and 80u.g/mL X-gal), with two plates per transformation reaction. The six
plates were labeled la, lb, 2a, 2b, 3a, and 3b and were allowed to incubate at 37°C
overnight. Following the incubation period, the plates were stored at 4°C.

Inoculation of Colonies into LB Broth
Two white colonies from each plate were chosen for culture. These colonies were
labeled lal, la2, lbl, lb2, 2al, 2a2, 2bl, 2b2, 3al, 3a2, 3bl, and 3b2. Each clone was
inoculated into 2mL LB broth containing lOOug/mL ampicillin. The tubes were set in the
37°C shaker (set at 220rpm) overnight, after which the cultures were immediately
purified using the QIAspin Mini-prep Kit (QIAGEN). All cultures grew except that
inoculated with clone pTarget-bPL-2b2. During the purification process, the pelleted
DNA was reconstituted in sterile dH 2 0. The resulting purified DNA was stored at -20°C.

Restriction Digests
Each sample of purified DNA was digested with the restriction enzymes Kpn I and
BamH I in order to determine if it contained the bPL insert. Digestion with these two
enzymes would effectively separate the insert from the vector since the BamH I
recognition site was located 5' of the insert, while the Kpn I recognition site was located
3' of the insert. Another important reason for using these two enzymes was that there
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was only one recognition site for each in the entire recombinant molecule. Table 2.6
gives the components of one digestion reaction and a cocktail recipe for 12 digests.

Table 2.6. Components of a double digest using Kpn I and BamH I.
Component
Volume per digest
lOxNEBufferl
2ul
BSA(lmg/mL)
2ul
RNAse-free H 2 0
9ul
Kpn I
1 ui
BamH I
]jd

Each digest was carried out in a 0.5mL eppendorf tube. Digest mix was added to each of
the 11 eppendorf tubes at a volume of \5\il per tube. Next, 5ul purified DNA was added
to the respective tubes. The digests were incubated at 37° for 2 hours. In order to stop
the action of the enzymes, 4)j.l loading dye was added to each of the digests.

Gel Electrophoresis of Digested DNA
The digests, along with a lOObp ladder from GibcoBRL, were run on a 1% agarose gel
stained with ethidium bromide. Each of the digests was loaded into the appropriate well
and the gel was run at 275 V for 15 minutes. Photographs of the gel were taken using the
Chemilmager 4400 Low Light Imaging System.
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DNA Sequencing
Each clone appeared to contain the bPL insert, and was therefore sent to the
University of Maine DNA Sequencing Facility to be sequenced. The sequences returned
were analyzed using the MegaBLAST program provided by the National Center for
Biotechnology Information (NCBI).

Digest of pTarget-bPL-lb2 and pTarget-bPL-3al and Isolation of the bPL Gene
The results of the MegaBLAST showed that the bPL gene, although present, was in
the incorrect orientation. This made it necessary to remove the gene from the pTarget
vector for insertion into another mammalian expression vector, the pcDNA3.1(+) vector
from Invitrogen (Figure 2.3). Clones pTarget-bPL-lb2 and pTarget-bPL-3al were
chosen at random to digest. The double digest using the restriction enzymes Kpn I and
BamH I (Table 2.6) was again employed. The two digests were run on a 1% agarose gel
stained with ethidium bromide and the bPL DNA fragments were excised and purified
using the QIAquick Gel Extraction Kit (QIAGEN).

Digest and Purification of the pcDNA3.1(+) Vector
The pcDNA3.1 vector was also digested with Kpn I and BamH I. The reaction was
set up as shown in Table 2.7.
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Figure 2.3. Map of the pcDNA3.1 mammalian expression vector. This map is based on
the map provided by Invitrogen.
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Table 2.7. Restriction digest of the pcDNA3.1(+) vector.
Component
lOxNEBufferl
BSA(lmg/mL)
Sterile dH 2 0
Kpn I
BamHI

Volume
16ul
16ul
72ul
8ul
8ul

Added to the reaction mixture was 40ul pcDNA3.1(+) vector. The digest was incubated
at 37°C for four hours. Following the incubation period, the digest was set in a 60°C
water bath to stop the reaction. Purification was achieved through the use of the
QIAGEN PCR Purification Kit (QIAGEN).

Ligation of bPL into the pcDNA3.1(+) Vector and Transformation into E. coli
The protocol used previously to ligate the bPL gene into the pTarget vector (Table
2.5) was used again to ligate the bPL gene digested from the pTarget-bPL clones into the
pcDNA3.1 vector. The recombinant molecules were transformed into competent JM109
E. coli cells and the transformants were plated on LB/Amp plates. The resulting colonies
were cultured, purified, and digested with Kpn I and BamH I (as described) to confirm
the presence of the bPL inserts. Samples that appeared to have the insert were sent to the
University of Maine DNA Sequencing Lab to be sequenced. The sequences obtained
(Figure 2.4) were analyzed using MegaBLAST.

Production of Primers bPL-Start-Kpnl and bPL-Stop-BamHI
According to the pcDNA3.1 product manual, the insert must contain a Kozak
translation initiation sequence for proper initiation of translation to occur. It is critical to
have a G or A at position -3 and a G at position +4 (positions are relative to the start
28

codon). The pcDNA3.1-bPL-3a 1-2-1 sequence did have a G at position +4, but had a C
in place of the required G or A at position - 3 . In order to rectify this, new primers, bPLStart-Kpnl and bPL-Stop-BamHI, were designed. Primer bPL-Start-Kpnl (51
GTTCATGGTACCGCTATGGCTCCAGCATCTAGCC 3') also incorporated a Kpn I
recognition site (GGTACC) prior to the start codon. Primer bPL-Stop-BamHI (5'
GTACCTGGATCCTTAGCATGGGGTGAATCGGC 3') incorporated a Bamll I
recognition site (GGATCC) following the stop codon. The placement of these primers
can be seen in Figure 2.4.
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5' g g t a c c c c c g g g a a a g a t t c c t c c a t t c a g t c c c t g t t g g g c c a t c t c c c c a t c a g c a g c
s
ccatgggggccctttctaaggaggtaagtcagggacaacccggtagaggggtagtcgtcg
Kpn I

60

Sma I

bPL-Start-Kpnl
gttcatggtaccgct
a g t c c t c a t c c t g g g a t t t c t c t c c S M cc t c]atg]gctccagca tc tagcca t eg t g g g c
tcaggagtaggaccctaaagagaggt taggagtaccgaggtcgtagatcggtagcacccg

120

accagtggatttgtgaccttgttcgagggtcctgcctgctcctgctgctggtggtgtcaa
tggtcacctaaacactggaacaagctcccaggacggacgaggacgacgaccaccacagtt

180

atctactcttgtgccagggtgtggaggattatgcaccatactgtaaaaaccaacctggca
tagatgagaacacggtcccacacctcctaatacgtggtatgacatttttggttggaccgt

240

actgccggattccccttcaaagcctgtttgagagagcaacattggtggctagcaacaact
tgacggcctaaggggaagtttcggacaaactctctcgttgtaaccaccgatcgttgttga

300

ataggctcgccagggaaatgttcaatgaatttgacgaagccctattgaggttggttatca
t a t c c g a g c g g t c c c t t tacaagt tact taaactget t c g g g a t a a c t c c a a c c a a t a g t

360

gt t t g c t c c a c t c g t g g g a t g a a c c t c t g c a t c a g g c a g t c a c a g a g t tgt tgcacagga
caaacgaggtgagcaccctacttggagacgtagtccgtcagtgtctcaacaacgtgtcct

420

a t g g a g c c t c a c c t g a t a t c t t g g c a a g g g c t a a a g a g a t tgaggacaagaccaaa;gtac 480
t a c c t c g g a g t g g a c t a t a g a a c c g t tcccgat t tctctaactcctgt tctggt t tcatg
t t c t a g a a g g t g t g g a a a t g a t a c a a a a a a g g g t tcatcctggagagaagaagaacjiagc
a a g a t c t tccacacct t tactatgt 1111 tcccaagtaggaicctctcttct tct tgeteg

540

cctatccagtgtggtcagaaaagtcctccctgacagcagacgatgaggatgtgcgccaaa
ggataggtcacaccagtcttttcaggagggactgtcgtctgctactcctacacgcggttt

600

ctgccttttatagaatgttccactgcctacacagggattcgagtaaaattagcacctaca
g a e g g a a a a t a t e t t a c a a g g t g a c g g a t g t g t c c c t a a g c t c a t 11 taatcgtggatgt

660

t c a a t t t g c t t a a g t g c c g a t t cacccca t gcfTTaJgcccacaa t t a a c c c a a c c a g t c c t
agt taaacgaat t c a c g g c t a a g t g g g g t a c g a T T c g g g t g t t a a t t g g g t t g g t c a g g a
cctaggtccatg
bPL-Stop-BamFil

t'Ai

gagatggttagtgatgatccatcccgtcaaaagcttctttgagttttatagctctttaat
ctctaccaatcactactaggtagggcagttttcgaagaaactcaaaatatcgagaaatta

780

g c a t g t t t g g g t g t a a t g g g t c t c a a t c a c g e g t c t c g a g g c t a g c a a g g a t c c 3'
c g t a c a a a c c c a c a t t a c c c a g a g t t a g t g c g c a g a g c t c c g a t c g t t c c t a g g b'

834

Mlu I

Xho I

Nhe I

Bam H I

Figure 2.4. pcDNA3.1-bPL-3al-2-l sequence. The placement of the new primer
sequences (bPL-Start-Kpnl and bPL-Stop-BamHI) are indicated in bold and underlined.
The cut sites incorporated into the sequence from the pTarget vector are underlined either
once or twice
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PCR
A PCR was set up using pcDNA3.l-bPL-3a 1-2-1 as the template and bPL-Start-Kpnl
and bPL-Stop-BamHI as the primers (Table 2.8).

Table 2.8. PCR using pcDNA3.1-bPL-3al-2-l as the template.
Component
Volume
PCR buffer
88ul
Taq polymerase
2ul
bPL primer pair (5uM each)
4ul
pcDNA3.1-bPL-3al-2-l
8uJ

In order to make the bPL primer pair, 1 Oul of each primer (1 OOuM each) was added to
180ul H2O. The mixture was divided into four PCR tubes (25ul each) and the reaction
was run for 35 cycles using a 55°C annealing temperature in the PTC-100 Programmable
Thermal Controller. The PCR product was run on a 1.5% gel stained with ethidium
bromide at 172V for 13 minutes. The remaining 90ul of PCR product was purified using
the QIAquick PCR Purification Kit (QIAGEN) and the DNA was eluted with 40u1 buffer
EB (provided in the purification kit).

Restriction Digest of the PCR Product
A double digest using the restriction enzymes Kpn I and BamH I was performed on
the PCR product (Table 2.9).
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Table 2.9. Restriction digest of the PCR product using Kpn I and Bam 11 I.
Component
Volume
PCR product
20u1
Buffer NEB 1
lOul
lOOxBSA
lul
Kpn I
4ul
BamH I
4ul
Sterile dH2Q
6uJ

The reaction was incubated at 37°C for 30 minutes. In order to stop the action of the
enzymes, lOjul 6x dye was added to the PCR product digest. The sample was run on a
1.5% agarose gel stained with ethidium bromide at 172V for 13 minutes. The band
corresponding to the estimated size of the insert was excised from the gel and purified
using the QlAquick Gel Extraction Kit (QIAGEN). The DNA was eluted in 20ul buffer
EB (provided in the kit).

Ligation of the bPL Insert into the pcDNA3.1(+) Vector
A different protocol was used to ligate the new bPL insert into the pcDNA3.1(+)
vector. This protocol involved a 1:1 ligation of insertvector with 500ng DNA total.
Table 2.10 shows the reaction components. The mixture was incubated at 15°C
overnight (16-18 hours).
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Table 2.10. Ligation of the bPL insert into the pcDNA3.1(+) vector.
Component
Volume
PCR product
"
20ul
BSA(2mg/mL)
lul
Fresh 4mM ATP
2ul
Sterile dH 2 0
1 Oja.1
T4 Ligase
1 p.1
bPL insert
0.3ul
Cut pcDNA3.!(+) vector
3.7ul

Transformation of the Recombinant DNA into Competent E. coli cells
A different transformation technique was also employed. To a chilled tube was added
lOOul cold lOOmM Tris HC1 (pH 7.4), 20ul ligation reaction, and 200ul competent
DH5a E. coli cells. The tube was incubated on ice for 20 minutes, heatshocked for two
minutes at 42°C, and then allowed to stand at room temperature for 10 minutes. At the
end of the incubation period, 2mL LB broth was added. The mixture was incubated at
37°C in the shaker (set at 220rpm) for one hour, followed by centrifugation at 6000xg for
five minutes. The supernatant was decanted and the pellet resuspended in 200ul LB
broth. Samples (5ul and 50ul) were plated on LB/Amp plates with the concentration of
ampicillin at 50ug/mL. Three colonies were chosen for culture in LB broth containing
lOOug/mL ampicillin. The DNA was purified using the QIAquick Spin Mini-prep Kit
(QIAGEN) and the purified DNA was digested with Kpn I and BamH I (Table 2.6). The
digests were run on a 1% agarose gel stained with ethidium bromide and the gels were
photographed using the Chemilmager 4400 Low Light Imaging System. Samples
appearing to contain the bPL insert (based on apparent molecular weight) were sent to the
University of Maine DNA Sequencing Facility for sequencing and sequences were
analyzed using MegaBLAST provided by NCBI.
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Culture of the Mouse L929 Cells
Mouse L929 cells (ATCC) were obtained from Dr. Charles Moody and were
maintained in Medium 1640 (Sigma) supplemented with 10% calf serum and 1%
glutamine-penicillin- streptomycin (Sigma) in 25cm2 cell culture flasks. In order to pass
the cells, the media was removed and the cells were washed with enough Dulbecco's
Phosphate Buffered Saline (DPBS from Sigma) to completely cover the monolayer. The
cells were then incubated in trypsin-EDTA (Sigma) for one minute until they began to
round up. The trypsin-EDTA was then removed and the culture vessel was struck against
the palm in order to dislodge the remaining adherent cells. The cells were then
resuspended in 5mL complete media and counted using a hemocytometer. Cells were
seeded in a new 25cm flask at 5x 104 cells/mL with a final volume of 5mL complete
media per flask. The flasks were kept in a 37°C incubator at 6% CO2 until they were
confluent and needed to be passed again.

Optimization of Transfection
Mouse L929 cells were transfected with the pEGFP-N3 vector (Clontech) (Figure 2.5)
in order to determine the optimal transfection reagent, Tfx-20 or Tfx-50 (Promega), and
concentration of DNA to use with the cells. The day before the transfection was to take
place, two 24-well plates were seeded with 5xl0 4 cells/well in ImL complete media. The
plates were kept at 37°C and 6% C0 2 for 24 hours. Various amounts of purified vector
DNA (0.25, 0.50, 0.75, and 1.00 ng per well) were tested at two different charge ratios of
Tfx Reagent:DNA (2:1 and 4:1). One plate was used for transfection with Tfx-20 and the
other for transfection with Tfx-50. The transfections were set up as shown in Table 2.11,
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Human cytomegalovirus immediate
early promoter: bases 1-589

•
•

I

SV40 origin of replication: bases
2441-2576

Multiple cloning site: bases
591-665

ISV40 early promoter

Enhanced green fluorescent
protein gene: bases 668-1369

Kanamycin/neomycin resistance
gene

SV40 early mRNA
polyadenylation signal

Herpes simplex virus/thymidine
kinase polyadenylation signal

fl single-strand DNA origin:
bases 1645-2100

pUC plasmid replication
origin: bases 4004-4647

Bacterial promoter for
expression of Kanr gene

Figure 2.5. Map of the pEGFP-N3 vector. This map is based on the map provided by
Clontech.
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making up an adequate amount of mixture for 3.5 replicates of each DNA concentration
To begin, the incomplete media (media without calf serum or antibiotics) and plasmid
DNA were combined in sterile tubes and the tubes were vortexed. The transfection
reagents were then added and the tubes were vortexed again. The Tfx Reagent/DNA
mixtures were incubated for 15 minutes at room temperature. The complete media was
removed from the cells and 200ul of the appropriate mixture was added per well. The
layout of the 24-well plates is shown in Figure 2.6. The plates were incubated for one
hour, followed by the addition of 1 mL complete media to each well. The plates were
returned to the 37°C incubator (6% C0 2 ) for 48 hours. After the incubation period was
complete, the wells were viewed under a fluorescent microscope.

Table 2.11. Optimization of transfection.
2:1 charge ratio
Amount of pEGFP-N3 per well
0.25ug
0.50ng
0.75ug
Incomplete medium
695.6ul
691.lul
686.8|j.l
pEGFP-N3
1.8fa.l
3.7u1
5.4ul
Tfx Reagent
2^1
52uJ
7^1
4:1 charge ratio
Amount of pEGFP-N3 per well
0.25ug
0.50ug
0.75ug
Incomplete medium
693.0ul
685.9ul
679.0ul
pEGFP-N3
1.8ul
3.7ul
5.4ul
Tfx Reagent
52uJ
10.4ul
15.6ul
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1.00|qg
682.2ul
7.3ul
10.5ul
1 .OOug
671.7ul
7.3ul
21 .Qui
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Figure 2.6. Plate layout for the optimization of transfection study. Various amounts of
purified pEGFP-N3 DNA (0.25, 0.50, 0.75, and 1.00 ug per well) were tested at two
different charge ratios of Tfx Reagent:DNA (2:1 and 4:1). Two plates were set up in this
manner, one for Tfx-20 and the other for Tfx-50.

Transfection of the L929 Cells with Purified pcDNA3.1-bPL DNA
From the optimization of transfection study, it was concluded that the most favorable
results occurred with the Tfx-20 Reagent at a 2:1 charge ratio and 1.00ug DNA per well.
It was therefore decided that this was the combination that would be used in the
transfection of the mouse cells with the pcDNA3.1-bPL recombinant DNA. Twenty-four
hours before the transfection was to take place, a 24-well plate was seeded with L929
cells at 5x 104 cells/well in lmL of complete media. The transfection was carried out as
had been done for the optimization study, this time using 1.00ug pcDNA3.1 -bPL and a
charge ratio of 2:1 for every well. The media from the cells was collected and replaced
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with new media every 48 hours for ten days. The collected media was tested for the
presence of bPL using radioimmunoassay (Wallace, 1993).
In a second trial, twelve wells of a 24-well plate were transfected with lug
pcDNA3.1-bPL per well with a charge ratio of 2:1 Tfx-20 Reagent: DNA. The
remaining twelve wells were to act as the control, being monitored over the course of the
study for growth. At 12, 24, and 48 hours post-transfection, the media was collected
from three of the transfected wells and the cells were removed from the surface of the
flask (using trypsin-EDTA) and were counted. In addition to performing a total cell
count, the cells were stained with trypan blue in order to distinguish the number of dead
cells. At each collection point, the cells from three of the control wells were removed
and counted, once again staining with trypan blue.

Transfection of a New Batch of Mouse L929 Cells
A new batch of L929 cells was purchased from American Type Culture Collection.
The cells were thawed and cultured according to the manufacture's directions. These
new cells were transfected with pcDNA3.1-bPL. Media was removed from the cells 48
hours after the transfection reaction took place. The media was then assayed for the
presence of bPL (Wallace, 1993).
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Chapter 3
RESULTS

Production of the Recombinant bPL Molecule
bPL cDNA was isolated from the placental tissue of a Holstein dairy cow at day 90 of
gestation. The bPL gene was identified with the help of primers (bPL-F and bPL-R) that
were designed using a known bPL sequence reported by Yamakawa el al. (1990). PCR
techniques were then carried out in order to amplify the DNA fragment of interest. This
fragment, beginning and ending with the primers, would be composed of 847 nucleotides.
The fragment was cloned into the pTarget mammalian expression vector and the
recombinant molecule was transformed into competent JM109 E. coli cells. The
transformants were plated on LB/Amp/IPTG/X-gal plates, which allowed for blue-white
color screening of the clones (Table 3.1).

Table 3.1. Colonies resulting from the transformation of the recombinant pTargetbPL molecule into competent JM109 E. coli cells.
Plate
# white colonies
# blue colonies
Total # colonies
la
lb
2a
2b
3a

2
4
15
17
8

4
4
16
15
4

6
8
31
32
12

3b
7
I
14
Each of the three ligation reactions involving the pTarget vector and the bPL insert were
used in the transformation of the recombinant molecule into competent JM109 E. coli
cells. Two plates were made from each reaction.
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Two white colonies from each of the six plates were chosen for culture. The DNA
from the eleven colonies that grew was purified and the purified DNA was then digested
with the restriction enzymes BamH I and Kpn I. The digests were run on agarose (1 %)
gel electrophoresis (Figure 3.1).

...__ 850 bp
650 bp

3b2 3bl 3a2 3al 2bl 2a2 2al 1b2 Ibl la2 lal

Figure 3.1. Gel electrophoresis of the pTarget-bPL restriction digests. Eleven clones
were digested with Kpn I and BamH I and the digests, along with a lkb plus ladder
(GibcoBRL) were run on a 1% agarose gel stained with ethidium bromide. All eleven
clones appeared to contain the bPL insert (band at 800bp).

Each of the clones appeared to contain the bPL insert and all were sequenced by the
University of Maine DNA Sequencing Facility. The returned sequences (Figure 3.2)
were analyzed using the Mega BLAST program. Mega BLAST was able to align the
plus strands of our sequences with the minus strands of bPL sequences in the GenBank
database. This told us that our inserts were ligated into the pTarget vector in the incorrect
orientation (Figure 3.3). In order for proper transcription of the bPL gene to take place, it
was necessary to have the initiation codon (ATG) of the gene on the plus strand
following the transcriptional start site of the vector. In the pTarget-bPL recombinant
molecule, the ATG was on the minus strand.
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In order to rectify this, it was necessary to remove the bPL insert from the pTarget
vector and ligate it into another vector, the pcDNA3.1(+) vector. Two of the clones,
pTarget-bPL-lb2 and pTarget-bPL-3al, were chosen at random to digest. The new
vector was digested in such a manner that the insert had no choice but to ligate into the
vector in the correct orientation (Figure 3.4). The pTarget vector came from the
manufacturer already digested. This vector had been prepared by making a blunt cut and
adding thymine (T) overhangs, so that each end was identical. For this reason, the insert
was able to ligate into the vector in both the correct and incorrect orientations. The
pcDNA3.1(+) vector was preferable to the pTarget vector because we were able to digest
it ourselves with the enzymes appropriate for our research. In our case, we needed to
digest with BamH I and Kpn I so that the bPL insert would be ligated in the correct
orientation.
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1 cacccaaacatgcattaaagagctataaaactcaaagaagcttttgacgggatggatcat
61

60

c a c t a a c c a t c t c a g g a c t g g t t g g g t t a a t t g t g g g c t t a g c a t g g g g t g a a t c g g c a c 120

121

ttaagcaaattgatgtaggtgctaattttactcgaatccctgtgtaggcagtggaacatt

180

181

e t a t a a a a g g c a g t t t g g c g c a c a t c c t c a t c g t c t g c t g t c a g g g a g g a c t t t t c t g a c 240

241

c a c a c t g g a t a g g g c t c g t t c t t c t t c t c t c c a g g a t g a a c c c t t t t t t g t a t c a t t t c c 300

301 a c a c c t t c t a g a a g t a c t t t g g t c t t g t c c t c a a t c t c t t t a g c c c t t g c c a a g a t a t c a 360
361 g g t g a g g c t c c a t t c c t g t g c a a c a a c t c t g t g a c t g c c t g a t g c a g a g g t t c a t c c c a c 420
421

g a g t g g a g c a a a c t g a t a a c c a a c c t c a a t a g g g c t t c g t c a a a t t e a t t g a a c a t t t e c 480

481

c t g g c g a g c c t a t a g t t g t t g c t a g c c a c c a a t g t t g c t c t c t c a a a c a g g c t t t g a a g g 540

541 g g a a t c c g g c a g t t g c c a g g t t g g t t t t t a c a g v a t g g t g c a t a a t c c t c c a c a c c c t g g 600
601

c a c a a g a g t a g a t t t g a c a c c a c c a g c a g c a g g a g c a g g c a g g a c c c t c g a a c a a g g t c a 660

661

c a a a t c c a c t g g t g c c c a c g a t g g c t a g a t g c t g g a g c c a t g a g g a t t g g a g a g a a a t c c 720

721

c a g g a t g a g g a c t g c t g c t g a t g g g g a g a t g g c c c c a a c c a g g g a c t g a a t g g a g g a a t c 780

781

tttcccggggggtaccgtcgactgtggccgcgaattc

817

Figure 3.2. pTarget-bPL sequence. This sequence is 817 base pairs in length and
aligns with the minus strand of bPL sequences in the GenBank database.
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The bPL insert was ligated into the pcDNA3.1(+) vector using ligation reaction 1
(Table 2.5). The recombinant molecules were then transformed into competent E. coli
cells. Two plates were made from each reaction.
The five clones (Table 3.2) that resulted were cultured, and the DNA was purified and
digested with BamH I and Kpn I. The digests were run on gel electrophoresis (Figure
3.5).

HAVE

WANT

Figure 3.3. Possible scenarios of the ligation of the bPL insert with the pTarget vector.
The ATG of the bPL insert is on the minus strand of the recombinant molecule. In order
for proper transcription of the bPL gene to take place, it is necessary for the ATG of the
gene to be on the plus strand following the transcriptional start site of the vector.

43

Figure 3.4. Ligating the bPL insert into the vector in the correct orientation, a) restriction
digest of pTarget-bPL to remove the bPL insert, b) restriction digest of the pcDNA3.1 (+)
vector to prepare for ligation with the bPL insert, c) ligation of the bPL insert with the
pcDNA3.1(+) vector to form the recombinant pcDNA3.1-bPL molecule. The insert has
no choice but to ligate into the vector in the correct orientation.
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Table 3.2. Colonies resulting from the transformation of the recombinant
pcDNA3.1-bPL molecule into competent JM109 E. coli cells.
Plate
# white colonies
lb2-l
1
lb2-2
0
3al-l
2
3al-2
2

I 1

_ 800 bp
700 bp

Figure 3.5. Gel electrophoresis of the pcDNA3.1-bPL restriction digests. Five clones
were cultured and purified. The DNA was then digested with Kpn I and BamH I and the
digests were run, along with a lOObp ladder (GibcoBRL) on a 1% agarose gel stained
with ethidium bromide. Four of the five clones contain the bPL insert.

Four of the five clones appeared to contain the bPL insert and were sent to the
University of Maine DNA Sequencing Facility for sequencing. The returned sequences
(Figure 2.4) were analyzed using the Mega BLAST program. As expected. Mega
BLAST was able to align the plus strands of our sequences with the plus strands of bPL
sequences in the GenBank database.
In order for other studies to be performed using the recombinant pcDNA3.1 -bPL
recombinant molecule (vaccine production, etc.), it was necessary for the bPL gene to be
in-frame with the transcriptional start site of the pcDNA3.1(+) vector. As can be seen in
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Figure 3.6, the bPL insert was not in-frame with the transcriptional start site. Also, in
order for proper initiation to occur, it was necessary to have a G or A at position -3 and a
G at position +4. Our bPL gene had the G at position +4, but had a C at position - 3 .
Primers bPL-Start-Kpnl and bPL-Stop-BamHI were designed so as to remedy these
problems. As can be seen in Figure 3.7, the bPL insert was now in-frame with the
transcriptional start site of the pcDNA3.1(+) vector and there was a G at position - 3 .

transcriptional start site
TAG AGA ACC CAC TGC TTA CTG GCT TAT CGA AAT TAA TAC
GAC TCA CTA TAG GGA GAC CCA AGC TGG CTA GCG TTT AAA
CTT AAG CTT GGT ACC CCC GGG AAA GAT TCC TCC ATT CAG
Kpnl

TCC CTG TTG GGC CAT CTC CCC ATC AGC AGC AGT CCT CAT
CCT GGG ATT TCT CTC CAA TCC TCA TGG
-3

+4

Figure 3.6. ATG of pcDNA3.1-bPL is not in-frame with the transcriptional start site.
The start codon (ATG) of the bPL gene is not in-frame with the transcriptional start site
of the pcDNA3.1(+) vector. In order for proper initiation of translation to occur, there
must be an A or G at position -3 and a G at position +4. In this sequence, there was a C
at position - 3 . The Kpn I recognition site is outlined for reference.

transcriptional start site

TAG AGA ACC CAC TGC TTA CTG GCT TAT CGA AAT TAA TAC
GAC TCA CTA TAG GGA GAC CCA AGC TGG CTA GCG TTT AAA
CTT AAG CTT GGT ACC GCT ATG GCT
Kpn I

-3

+4

Figure 3.7. ATG of pcDNA3.1-bPL is in-frame with the transcriptional start site. The
start codon (ATG) of the bPL gene was in-frame with the transcriptional start site of the
pcDNA3.1(+) vector. The requirements for proper initiation have been met, with
guanines at positions -3 and +4.
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Description of the bPL Gene
The bPL cDNA isolated in this study (Figure 3.8) encoded an open reading frame
from the beginning of the clone to the termination codon (TAA) at nucleotide positions
670-672. The sequence shown here includes a small number of nucleotides belonging to
the vector sequence, including the Kpn I and BamH I recognition sites. There was a
single ATG at nucleotide positions 10-12, which was thought to be the initiating
methionine. This predicts a preprohormone of 200 amino acids.
Mega BLAST was able to align the plus strand of our bPL sequence with the plus
strand of a bPL sequence reported by Schuler et al. (1988), which predicted a
preprohormone of 236 amino acids. The comparison of the two preprohormone
sequences is given in Figure 3.9. Schuler et al. (1988) were able to divide their bPL
sequence into five exons. When aligned with the Schuler sequence, it is evident that the
bPL sequence of this study was missing the entire third exon. Schuler and her colleagues
(1988) were also able to identify the first exon as the signal peptide, with the site of
cleavage following the glycine at amino acid 36. Their mature hormone would therefore
be 200 amino acids in length. In comparison, our mature protein would be 164 amino
acids.
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1 ggtaccgctatggctccagcatctagccatcgtgggcaccagtggatttgtgaccttgtt
Kpn I

bu

61 c g a g g g t c c t g c c t g c t c c t g c t g c t g g t g g t g t c a a a t c t a c t c t t g t g c c a g g g t g t g

120

121 g a g g a t t a t g c a c c a t a c t g t a a a a a c c a a c c t g g c a a c t g c c g g a t t c c c c t t c a a a g c 180
181 c t g t t t g a g a g a g c a a c a t t g g t g g c t a g c a a c a a c t a t a g g c t c g c c a g g g a a a t g t t c 240
241 a a t g a a t t t g a c g a a g c c c t a t t g a g g t t g g t t a t c a g t t t g c t c c a c t c g t g g g a t g a a 300
301 c c t c t g c a t c a g g c a g t c a c a g c g t t g t t g c a c a g g a a t g g a g c c t c a c c t g a t a t c t t g 360
361 g c a a g g g c t a a a g a g a t t g a g g a c a a g a c c a a a g t a c t t c t a g a a g g t g t g g a a a t g a t a 420
421 c a a a a a a g g g t t c a t c c t g g a g a g a a g a a g a a c g a g c c c t a t c c a g t g t g g t c a g a a a a g 480
481 t c c t c c c t g a c a g c a g a c g a t g a g g a t g t g c g c c a a a c t g c c t t t t a t a g a a t g t t c c a c 540
541 t g c c t a c a c a g g g a t t c g a g t a a a a t t a g c a c c t a c a t c a a t t t g c t t a a g t g c c g a t t c 600
eui a c c c c a t g c t a a g g a t c c a c t a g t c c a g t g t g g t g g a a t t c

b4i

BamH I

Figure 3.8. pcDNA3.1-bPL sequence. The start codon (ATG) and stop codon (TAA)
are underlined. The Kpn I and BamH I recognition sites are underlined twice for
reference.
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a t g g c t c c a g c a t c t a g c c a t c g t g g g c a c c a g t g g a t t t g t g a c c t tgt t c g a g g g t c c
MetAlaProAlaSerSerHlsArgGlyHlsGlnTrplleCysAspLeuValArgGlySer

tgcctgctcctgctgctggtggtgtcaaatctactcttgtgccagggt
CysLeuLeuLeuLeuLeuValValSerAsnLeuLeuLeuCysGlnGly

Va I
.t
g c g g a g g a t tat
A I a G I u A s pTy r

g c a c c a t a c t g t a a a a a c c a a c c t g g c a a c t g c c g g a t tcccct t c a a a g c c t g t t tgag
AlaProTyrCysLysAsnGlnProGlyAsnCysArglleProLeuGlnSerLeuPheGlu
agagcaacat tggtggctagcaacaactataggctcgccagggaaatgt tcaatgaat t t
ArgAIaTh r LeuVaIAIaSe rAsnAsnTy rArgLeuAIaArgGIuMe tPheAsnGIuPhe
a a t a a a c a g t t t g g c g a g g g c a a a a a c t tcact tccaagt t c a t c a a c a g c t g c c a c a c c
AsnLysGlnPheGlyGluGlyLysAsnPheThrSerLysPhelleAsnSerCysHlsThr
gaattcatgactacccctaataacaaagaagcagctgcaaatacagag
GluPheMetThrThrProAsnAsnLysGluAlaAlaAlaAsnThrGlu

gacgaagccctg
A s p G I u A I a Le u

t t g a g g t tggt t a t c a g t t t g c t c c a c t c g t g g g a t g a a c c t c t g c a t c a g g c a g t c a c a
LeuArgLeuValIleSerLeuLeuHlsSerTrpAspGIuProLeuHlsGInAIaVaIThr
g a g t tgt t g c a c a g g a a t g g a g c c t c a c c t g a t a t c t t g g c a a g g g c t a a a g a g a t t g a g
G l u L e u L e u H l s A r g A s n G l y A l a S e r P r o A s p l l e L e u A l a A r g A l a L y s G l u l leGlu
gacaagaccaaagtacttctagaaggtgtggaaatgatacaaaaaagg
AspLysThrLysValLeuLeuGluGlyValGluMetIleGlnLysArg

gt t c a t c c t g g a
VaIHIsProG I y

gagaagaagaacgagccctatccagtgtggtcagaaaagtcctccctgacagcagacgat
GluLysLysAsnGluProTyrProValTrpSerGluLysSerSerLeuThrAlaAspAsp
gaggatgtgcgccaaactgccttttatagaatgttccactgcctacacagggattcgagt
GluAspValArgGlnThrAlaPheTyrArgMetPheHlsCysLeuHlsArgAspSerSer
aaaattagcacctacatcaatttgcttaagtgccgattcaccccatgc
Lysl l e S e r T h r T y r l
leAsnLeuLeuLysCysArgPheThrProCys

Figure 3.9. Comparison of two bPL preprohormone sequences. The sequence given
is that reported by Schuler et al (1988), along with the corresponding amino acid
sequence. This sequence was made up of five exons, divided by the vertical lines. The
dots represent nucleotides of the pcDNA3.1-bPL sequence that match the Schuler
sequence, while the equal signs represent the missing third exon of pcDNA3.1-bPL.
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The results of the optimization of transfection study are shown in Figures 3.10 and
3.11. As can be seen, the L929 cells that were transfected with a 2:1 charge ration of
Tfx-20:DNA and 1 .OOug pEGFP-N3 per well produced the most favorable results. As
can be seen in Figure 3.10, a greater number of cells transfected with this combination
could be visualized under the fluorescent microscope. This results from a greater
transfection efficiency. For this reason, this combination of charge ration and
concentration of DNA was used in the transfection of the cells with the pcDNA3.1-bPL.
The L929 cells were transfected with a 2:1 charge ratio of Tfx-20:DNA and 1 .OOug
pcDNA3.1 -bPL per well. The media from the cells was collected and replaced with new
media every 48 hours for ten days. Using radioimmunoassay (Wallace, 1993), it was
determined that there was an average of 1 .OOng bPL per milliliter of collected media. It
had been hypothesized that the cells would be able to produce at least 1 OOng bPL per
milliliter media (unpublished results using mouse L cells). It was noted throughout the
collection of the media that the L929 cells were not growing at the expected rate. In
order to determine the reason for this, another transfection of the cells with the
pcDNA3.1-bPL was carried out, this time also maintaining nontransfected control wells.
Media collection began 12 hours post-transfection, followed by collection at 24 and 48
hours post-transfection. At the time of media collection, the cells were trypsinized and
stained with trypan blue in order to distinguish between the live and dead cells. The
results of this study are shown in Table 3.3 and Figure 3.12.
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Figure 3.10. Optimization of transfection with Tfx-20. The combination of the 2:1 charge ratio and l.OOug DNA/well produced the
highest transfection efficiency.

Figure 3.11. Optimization of transfection with Tfx-50. The combination of the 2:1 charge ratio and 0.50ug DNA/well produced the
highest transfection efficiency.

Table 3.3. Post-transfection cell viability results
Hours postLive cells
Dead cells
transfection
(cells/mL)
(cells/mL)
Control wells
12
564,000
0
24
724,000
0
48
1,928,000
8,000
Transfected wells

Total cells
(cells/mL)

Cell viability
(% cell/mL)

564,000
724,000
1,936,000

100
100
99.59

12
456,000
8,000
464,000
98.28
24
388,000
8,000
396,000
97.98
48
576,000
4,000
580,000
99.31
At the indicated times, the cells from three wells of each of the groups (control and
transfected) were trypsinized. The cells were pooled according to group, stained with
trypan blue, and counted.
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Figure 3.12. Growth rate of transfected and non-transfected L929 cells. The total
number of cells per milliliter of media 12 to 48 hours post-transfection.
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The cell viabilities of both the control and the transfected wells were comparable. The
lowest cell viability noted in the control wells was 99.59% at 48 hours post-transfection
and the lowest in the transfected wells was 97.98% at 24 hours post-transfection. Despite
the similar cell viabilities, it is clear from Figure 3.12 that the cells of the nontransfected
control wells were growing at a faster rate than the cells of the transfected wells. By 48
hours post-transfection, the number of control cells exceeded the number of transfected
cells by 1,356,000 cells/mL. This seemed to point to the conclusion that the transfection
was somehow altering the growth rate of the mouse cells.
Due to the slow growth rate of the L929 cells and the low transfection efficiency, it
was believed that the cells were carrying a mycoplasma infection. Therefore, a new
batch of L929 cells was purchased from American Type Culture Collection and the cells
were transfected with pcDNA3.1-bPL. Media was collected 48 hours post-transfection
and was assayed for the presence of bPL (Wallace, 1993). The radioimmunoassay was
unable to detect any bPL in the media. However, at 48 hours post-transfection, the cells
appeared healthy and had grown to confluency.
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Chapter 4
DISCUSSION

Recombinant DNA technology has enabled advances in a myriad of research interests.
Proteins that would have, at one time, been difficult to study, are now being produced in
laboratories all over the world. Bovine placental lactogen, a hormone whose peak
concentrations are reported at a mere 2.93ng/mL (Wallace, 1993), is no exception. The
production of recombinant bPL (rbPL) has allowed researchers to delve into the structure
and function of this mysterious protein, and many discoveries have been made. Sitedirected mutagenesis of rbPL has made it possible to pinpoint exact locations on the
protein that are important in receptor binding (Vashdi-Elberg et al, 1996; Helman et al,
1997). The N-terminal portion of bPL, which is not present in growth hormone, has been
identified as being important in PRL receptor binding (Gertler et al, 1992). bPL has also
been labeled as a key factor in the regulation of mammary growth and differentiation
(Byatt et al, 1994; Byatt et al, 1997) and in the stimulation of body weight gain (Byatt et
al, 1991). In addition, rbPL has been used to study the effects of the hormone on the
growth and function of heifer ovaries (Lucy et al, 1994).
Despite these developments, there is one possible downfall to the work that has been
done with rbPL thus far. The rbPL used in the aforementioned studies was produced in
bacteria, an expression system that may not be capable of carrying out all of the posttranslational modifications that are important to the function of the protein.
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In this study, we were able to isolate bPL cDNA from the placental tissue of a
Holstein dairy cow at day 90 of gestation. We cloned the cDNA into the pcDNA3.1(+)
vector and transformed the recombinant DNA into E. coli cells. The bPL sequence
isolated in this study was similar to that isolated by Schuler el al. (1988). The Schuler
sequence predicted a preprohormone of 236 amino acids and could be divided into five
exons. Our sequence, however, predicted a preprohormone of only 200 amino acids.
Upon further analysis of our sequence, it was evident that it was missing the entire third
exon, as was the sequence isolated by Kessler and Schuler (1991). Kessler and Schuler
noted that the third exon contains one of the six cysteine residues important to the
conformation of the mature bPL protein. Although no further research has been reported
on that particular variant, it was predicted that the missing third exon may change the
folding pattern of the protein, thus rendering it inactive (Kessler and Schuler, 1991).
The initial transfection of the recombinant bPL molecule produced much lower yields
of the protein than expected (as measured by radioimmunoassay (Wallace, 1993)). It was
noted during the collection of data that the transfected cells were not achieving
confluence at the typical rate. Two hypotheses were established in order to try to explain
the poor results: 1) the cells were experiencing some toxicity, caused either by the
transfection agent or by the bPL and 2) the cells were not dividing properly. It was
assumed that toxicity would result in low cell viability counts, whereas slow growth and
division would result in low total cell counts, with high viability. The latter was the
result that was observed. In the second transfection trial, when compared to the control
group, the transfected cells were significantly less in number, but still maintained a high
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viability level. This seemed to point to the conclusion that there was something slowing
cell division in the transfected cultures.
In a similar study, Xia et al (1997) observed decreased transfection efficiency and
slow growth of apparently healthy COS cells. It was concluded that the results obtained
were caused by a mycoplasma infection. Mycoplasma are parasitic prokaryotic
organisms that are resistant to penicillin-type antibiotics (Rottem, 1980). This means that
they are able to survive in cell cultures with media containing such antibiotics. The
typical energy source utilized by mycoplasma is arginine. The utilization of arginine is
mediated by the enzyme arginine deiminase (Sugimura et al, 1992; Sugimura et al,
1993). Arginine deiminase activity is thought to disrupt normal vesicular trafficking in
cells, thus disrupting the liposomal-mediated transfection process (Xia el al, 1997).
Although the L929 cells were not tested for mycoplasma infection, it is assumed that this
was the cause of the decreased growth rate of the transfected population. A new batch of
L929 cells tested for the presence of mycoplasma before purchase were able to grow to
confluence by 48 hours post-transfection.
Despite the fact that the new cells appeared to be free of mycoplasma, they still were
unable to produce the bPL. This led us to believe that there was a problem with the bPL
sequence that we were using in the transfection. As stated in Chapter 2: Methods and
Materials, in order to prepare the sequence for the production of a vaccine also needed in
Dr. Wallace's lab, the sequence 5' to the start codon was removed. Liang et al (1999) in
their study of ovine placental lactogen (oPL), concluded that the 1.1 kb 5'-flanking
sequence , and most importantly, the proximal 383 bp of the oPL gene 5'-flanking
sequence, was key to the transactivation of the oPL gene. In contrast to the lengthy 5'-
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flanking sequence of oPL, the bPL gene 5'-flanking sequence reported by Schuler et al.
(1988) was 78 bp. Wallis (1993) noted a rapid rate of molecular evolution of ruminant
placental lactogens. According to comparisons of the amino acid sequences for ovine
and bovine PLs (Calosi et al, 1989; Schuler et al, 1988), these two hormones differ in
about 30% of all residues. The structural differences between the ruminant PLs deem it
difficult to draw conclusions about bPL by making comparisons to oPL. For this reason,
the next step in the quest for the successful transfection and production of bPL should be
to fashion a bPL study after the oPL study done by Liang et al (1999). Such a study
would enable us to see if the 5'-flanking sequence of the bPL gene is required for the
production of the bPL protein, and if so, which particular region(s) are of the most
importance.
Ideally, a full-length bPL sequence should be isolated and cloned. The transfection of
the full-length sequence, and thus production of the full-length protein, would enable
comparisons to be made between the it and the proteins resulting from the alternatively
spliced genes. Overall, the production of bPL in the laboratory through the use of
transfection will enable researchers to further explore the importance of the different
structures and functions of this protein.
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